Organon (OGN) Share-based Compensation (2020 - 2026)
Organon (OGN) posted quarterly Share-based Compensation of $25.0 million for Q2 2026, up 13.64% year-over-year from $22.0 million in Q2 2025, and up 31.58% on a QoQ basis from $19.0 million in Q1 2026.
Organon (OGN) Share-based Compensation (2020 - 2026) Analysis & Trends
Organon has reported Share-based Compensation for 7 years, with the latest figure at $25.0 million in Q2 2026.
- Share-based Compensation for Q2 2026 came in at $25.0 million, up 13.64% year-over-year; the trailing twelve-month figure through Jun 2026 was $75.0 million (down 22.68% YoY), and the FY2025 annual result was $77.0 million, down 45.39% from the prior year.
- Share-based Compensation climbed to $25.0 million in Q2 2026, from $19.0 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $28.0 million in Q2 2024 and troughed at $7.0 million in Q4 2025.
- A 5-year average of $22.3 million and a median of $24.0 million in 2025 frame the typical range for Share-based Compensation.
- The widest annual swing landed in 2022, when Share-based Compensation jumped 53.33%; it then tumbled 73.08% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $23.0 million in 2022, then gained by 17.39% to $27.0 million in 2023, then declined by 3.7% to $26.0 million in 2024, then plunged by 73.08% to $7.0 million in 2025, then soared by 257.14% to $25.0 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $25.0 million in Q2 2026, $19.0 million in Q1 2026, and $7.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn | - |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 25.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.00 Mn |
| Jun 30, 2026 | 25.00 Mn |
| Mar 31, 2026 | 19.00 Mn |
| Mar 31, 2026 | 19.00 Mn |
| Dec 31, 2025 | -55.00 Mn |
| Dec 31, 2025 | -55.00 Mn |
| Sep 30, 2025 | 57.00 Mn |
| Sep 30, 2025 | 57.00 Mn |
| Jun 30, 2025 | -11.00 Mn |
| Jun 30, 2025 | -11.00 Mn |
| Mar 31, 2025 | 24.00 Mn |
| Mar 31, 2025 | 24.00 Mn |
| Dec 31, 2024 | -57.00 Mn |
| Dec 31, 2024 | -57.00 Mn |
| Sep 30, 2024 | 63.00 Mn |
| Sep 30, 2024 | 63.00 Mn |
| Jun 30, 2024 | -10.00 Mn |
| Jun 30, 2024 | -10.00 Mn |
| Mar 31, 2024 | 26.00 Mn |
| Mar 31, 2024 | 26.00 Mn |